Lumida
/BCAX
⌘K
Bicara Therapeutics Inc

Bicara Therapeutics Inc

BCAX
$22.81USD-1.26%-0.29 today

MARKET CAP

1.5B

P/E (TTM)

FWD P/E

DAY RANGE

$22 – $24

52W RANGE

$10
$31

AI Summary

Stalk
Sell NowMedium

BCAX remains in a Stage 3 distribution with sequential lower highs and lower lows beneath declining 9/20/50 EMAs, reflecting supply dominance. Medium-term bias is bearish, favoring sell-side engagement on rallies into the EMA cluster. Short-term weakness and repeated rejection at overhead EMAs confirm immediate sell-now timing despite extreme oversold conditions.

  • 13F ownership score of 1.90 indicates strong institutional backing.
  • Momentum score of 1.58 reflects one-year price outperformance.
  • Profitability score at –2.25 highlights weak operating margins.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Command is a leading player in the technology sector, specializing in cloud computing and artificial intelligence (AI) solutions. Positioned at the forefront of the digital transformation era, Command leverages its advanced AI capabilities to offer robust data-driven services across various industries, enhancing operational efficiencies and customer engagement. The company is prominently part of the ongoing tech revolution, riding the wave of increasing adoption of AI technologies in enterprise applications.

Bull says

  • 13F ownership score of 1.90 indicates strong institutional backing.
  • Momentum score of 1.58 reflects one-year price outperformance.
  • Liquidity score of 0.70 ensures easy entry and exit.
  • Growing AI adoption drives long-term revenue growth potential.
  • Robust liquidity positions company for share repurchases.
  • AI solutions market leadership underpins strategic upside.

Bear says

  • Profitability score at –2.25 highlights weak operating margins.
  • Earnings yield is negative, signaling poor return generation.
  • Revisions score of –1.73 forecasts potential earnings downgrades.
  • Leverage score of –1.88 indicates elevated debt risk.
  • Balance-sheet quality score of –1.31 raises solvency worries.
  • Volatility score of 1.57 suggests susceptibility to sharp swings.

Investment themes with BCAX

Biotech -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q4 2025 · Mgmt. Guidance

Updated 08-11-2026neutral

Transcript signals

Read full transcript analysis ›